152 related articles for article (PubMed ID: 34495459)
1. Distinct genetic landscape and a low response to doxorubicin in a luminal-A breast cancer cell line of Pakistani origin.
Shakeel M; Khan SA; Mughal AJ; Irfan M; Hoessli DC; Choudhary MI; Aurongzeb M; Khan IA
Mol Biol Rep; 2021 Oct; 48(10):6821-6829. PubMed ID: 34495459
[TBL] [Abstract][Full Text] [Related]
2. The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Marchiò C; Geyer FC; Ng CK; Piscuoglio S; De Filippo MR; Cupo M; Schultheis AM; Lim RS; Burke KA; Guerini-Rocco E; Papotti M; Norton L; Sapino A; Weigelt B; Reis-Filho JS
J Pathol; 2017 Feb; 241(3):405-419. PubMed ID: 27925203
[TBL] [Abstract][Full Text] [Related]
3. The Genomic Landscape of Male Breast Cancers.
Piscuoglio S; Ng CK; Murray MP; Guerini-Rocco E; Martelotto LG; Geyer FC; Bidard FC; Berman S; Fusco N; Sakr RA; Eberle CA; De Mattos-Arruda L; Macedo GS; Akram M; Baslan T; Hicks JB; King TA; Brogi E; Norton L; Weigelt B; Hudis CA; Reis-Filho JS
Clin Cancer Res; 2016 Aug; 22(16):4045-56. PubMed ID: 26960396
[TBL] [Abstract][Full Text] [Related]
4. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
5. Divergence of mutational signatures in association with breast cancer subtype.
Perry G; Dadiani M; Kahana-Edwin S; Pavlovski A; Markus B; Hornung G; Balint-Lahat N; Yosepovich A; Hout-Siloni G; Jacob-Hirsch J; Sklair-Levy M; Friedman E; Barshack I; Kaufman B; Gal-Yam EN; Paluch-Shimon S
Mol Carcinog; 2022 Nov; 61(11):1056-1070. PubMed ID: 36111610
[TBL] [Abstract][Full Text] [Related]
6. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Liu S; Wang H; Zhang L; Tang C; Jones L; Ye H; Ban L; Wang A; Liu Z; Lou F; Zhang D; Sun H; Dong H; Zhang G; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Huang XF; Chen SY; Zhou T
Hum Genomics; 2015 Feb; 9(1):2. PubMed ID: 25757876
[TBL] [Abstract][Full Text] [Related]
7. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin.
Koehn H; Magan N; Isaacs RJ; Stowell KM
Anticancer Drugs; 2007 Apr; 18(4):419-25. PubMed ID: 17351394
[TBL] [Abstract][Full Text] [Related]
8. Immune gene expression profiling reveals heterogeneity in luminal breast tumors.
Zhu B; Tse LA; Wang D; Koka H; Zhang T; Abubakar M; Lee P; Wang F; Wu C; Tsang KH; Chan WC; Law SH; Li M; Li W; Wu S; Liu Z; Huang B; Zhang H; Tang E; Kan Z; Lee S; Park YH; Nam SJ; Wang M; Sun X; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Shi J; Garcia-Closas M; Chanock S; Yang XR
Breast Cancer Res; 2019 Dec; 21(1):147. PubMed ID: 31856876
[TBL] [Abstract][Full Text] [Related]
9. A Tumor initiating cell-enriched prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions.
Liu JC; Egan SE; Zacksenhaus E
Oncotarget; 2013 Aug; 4(8):1317-28. PubMed ID: 23945331
[TBL] [Abstract][Full Text] [Related]
10. Uncovering the genomic heterogeneity of multifocal breast cancer.
Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Chen B; Zhang G; Wei G; Wang Y; Guo L; Lin J; Li K; Mok H; Cao L; Ren C; Wen L; Jia M; Li C; Hou T; Han-Zhang H; Liu J; Balch CM; Liao N
Endocr Relat Cancer; 2020 Mar; 27(3):153-162. PubMed ID: 31905165
[TBL] [Abstract][Full Text] [Related]
12. Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.
Gatza ML; Kung HN; Blackwell KL; Dewhirst MW; Marks JR; Chi JT
Breast Cancer Res; 2011 Jun; 13(3):R62. PubMed ID: 21672245
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer onco-signatures reveal a novel mitochondrial subtype of luminal breast cancer with specific regulators.
Simeone I; Ceccarelli M
J Transl Med; 2023 Jan; 21(1):55. PubMed ID: 36717859
[TBL] [Abstract][Full Text] [Related]
14. Genomic characterization of metastatic breast cancers.
Bertucci F; Ng CKY; Patsouris A; Droin N; Piscuoglio S; Carbuccia N; Soria JC; Dien AT; Adnani Y; Kamal M; Garnier S; Meurice G; Jimenez M; Dogan S; Verret B; Chaffanet M; Bachelot T; Campone M; Lefeuvre C; Bonnefoi H; Dalenc F; Jacquet A; De Filippo MR; Babbar N; Birnbaum D; Filleron T; Le Tourneau C; André F
Nature; 2019 May; 569(7757):560-564. PubMed ID: 31118521
[TBL] [Abstract][Full Text] [Related]
15. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
16. Gene expression patterns associated with p53 status in breast cancer.
Troester MA; Herschkowitz JI; Oh DS; He X; Hoadley KA; Barbier CS; Perou CM
BMC Cancer; 2006 Dec; 6():276. PubMed ID: 17150101
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
[TBL] [Abstract][Full Text] [Related]
18. Exomes of Ductal Luminal Breast Cancer Patients from Southwest Colombia: Gene Mutational Profile and Related Expression Alterations.
Cortes-Urrea C; Bueno-Gutiérrez F; Solarte M; Guevara-Burbano M; Tobar-Tosse F; Vélez-Varela PE; Bonilla JC; Barreto G; Velasco-Medina J; Moreno PA; Rivas JL
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32365829
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors.
Sawasdee N; Wattanapanitch M; Thongsin N; Phanthaphol N; Chiawpanit C; Thuwajit C; Yenchitsomanus PT; Panya A
Int J Mol Med; 2022 Mar; 49(3):. PubMed ID: 35119077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
